Unknown

Dataset Information

0

Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study.


ABSTRACT: Background:Venetoclax is a selective, potent inhibitor of the anti-apoptotic B-cell leukemia/lymphoma-2 protein approved for treatment of chronic lymphocytic leukemia. We conducted a dose-finding study of venetoclax in combination with bendamustine-rituximab (BR) in patients with relapsed/refractory non-Hodgkin's lymphoma (NHL). Patients and methods:BR was given for six cycles at standard doses. Intermittent and continuous oral venetoclax administration was explored at 50-1200?mg daily doses. Co-primary objectives included safety, pharmacokinetics (PKs), maximum-tolerated dose (MTD), and recommended phase II dose (RP2D); secondary objective was preliminary efficacy. Results:Sixty patients were enrolled: 32 with follicular lymphoma, 22 with diffuse large B-cell lymphoma, and 6 with marginal zone lymphoma. Nausea (70%), neutropenia (68%), diarrhea (55%), and thrombocytopenia (52%) were the most frequent adverse events (AEs). Most common grade 3/4 AEs were neutropenia (60%) and lymphopenia (38%). Serious AEs were reported in 24 patients; the most frequent were febrile neutropenia and disease progression (8% each). Five patients died from either disease progression (n?=?4) or respiratory failure (n?=?1). MTD was not reached; RP2D for venetoclax-BR combination was established as 800?mg daily continuously. Venetoclax PK exposure with and without BR was comparable. For all patients, overall response rate was 65%. Median duration of overall response, overall survival, and progression-free survival was 38.3?months [95% confidence interval (CI) 10.4-NR], not yet reached, and 10.7?months (95% CI 4.3-21.0), respectively. Conclusions:This study established the safety profile of venetoclax in combination with BR, and results demonstrated tolerability and preliminary efficacy of the combination. Additional follow-up is needed to better determine the future role of BR plus venetoclax in the treatment of relapsed/refractory B-cell NHL. Trial registered:Clinicaltrials.gov, NCT01594229.

SUBMITTER: de Vos S 

PROVIDER: S-EPMC6158762 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study.

de Vos S S   Swinnen L J LJ   Wang D D   Reid E E   Fowler N N   Cordero J J   Dunbar M M   Enschede S H SH   Nolan C C   Petrich A M AM   Ross J A JA   Salem A H AH   Verdugo M M   Agarwal S S   Zhou L L   Kozloff M M   Nastoupil L J LJ   Flowers C R CR  

Annals of oncology : official journal of the European Society for Medical Oncology 20180901 9


<h4>Background</h4>Venetoclax is a selective, potent inhibitor of the anti-apoptotic B-cell leukemia/lymphoma-2 protein approved for treatment of chronic lymphocytic leukemia. We conducted a dose-finding study of venetoclax in combination with bendamustine-rituximab (BR) in patients with relapsed/refractory non-Hodgkin's lymphoma (NHL).<h4>Patients and methods</h4>BR was given for six cycles at standard doses. Intermittent and continuous oral venetoclax administration was explored at 50-1200 mg  ...[more]

Similar Datasets

| S-EPMC7735159 | biostudies-literature
| S-EPMC8905688 | biostudies-literature
| S-EPMC3861900 | biostudies-literature
| S-EPMC8253277 | biostudies-literature
| S-EPMC5027960 | biostudies-literature
| S-EPMC6886437 | biostudies-literature
| S-EPMC3862960 | biostudies-literature
| S-EPMC3918114 | biostudies-literature
| S-EPMC8993776 | biostudies-literature
| S-EPMC9412011 | biostudies-literature